Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) Bundle
Founded in 1997 and operating under Guangzhou Pharmaceutical Holdings Limited, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has grown into a pharmaceutical powerhouse with a workforce of over 28,000, segmented into Great Southern TCM, Great Commerce and Great Health to cover Chinese patent medicines, Western and biological drugs, chemical raw materials and health products; guided by the mission "caring for life and pursuing excellence" and the vision of "spreading love all over the world", GBPHC backed its patient-centric strategy with an R&D spend of 2.5 billion RMB in 2023, lifted its brand value by 11% to USD 2.5 billion in Brand Finance's Chinese Pharma 15 2024 report, and commits to sustainability targets including carbon peak by 2030 and carbon neutrality by 2060 while living its core values of cooperation, relief, honesty, dedication, diligence and innovation.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) Intro
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) is a leading Chinese pharmaceutical conglomerate engaged in the research, development, manufacturing and sales of Chinese patent medicines, Western medicines, chemical raw materials, natural medicines, biological medicines and health products. Established in 1997 and operating under Guangzhou Pharmaceutical Holdings Limited (GPHL), the company has grown into one of China's largest pharmaceutical groups with a workforce exceeding 28,000 employees and diversified operations structured across strategic business segments.| Item | Detail |
|---|---|
| Ticker | 0874.HK |
| Founded | 1997 |
| Parent | Guangzhou Pharmaceutical Holdings Limited (GPHL) |
| Employees | Over 28,000 |
| Key segments | Great Southern TCM; Great Commerce; Great Health |
| R&D expenditure (2023) | Approximately RMB 2.5 billion |
| Brand value (2024) | USD 2.5 billion (Brand Finance Chinese Pharma 15 2024; +11% YoY) |
| Sustainability targets | Carbon peak by 2030; carbon neutrality by 2060 |
- Mission: To improve public health through integrated pharmaceutical innovation, dependable manufacturing and widely accessible healthcare solutions that combine traditional Chinese medicine and modern biopharmaceutical approaches.
- Vision: To be a globally respected pharmaceutical leader rooted in Chinese medicinal heritage and modern R&D excellence, delivering sustainable value to patients, partners and society.
- Core Values:
- Patient-centricity - prioritizing safety, efficacy and access.
- Innovation - sustained investment in R&D and technology (R&D spend ~RMB 2.5bn in 2023).
- Integrity - regulatory compliance and quality-driven manufacturing.
- Collaboration - cross-segment synergy across Great Southern TCM, Great Commerce and Great Health.
- Sustainability - aligning operations with carbon peak (2030) and neutrality (2060) commitments.
- Portfolio balance between traditional Chinese medicines and modern pharmaceuticals to capture both domestic demand and export potential.
- Scale manufacturing and supply-chain integration supported by the Great Commerce segment to improve distribution efficiency and market reach.
- Health and wellness extension via Great Health: nutraceuticals, consumer health products and service offerings tapping aging-population and chronic-disease trends.
- R&D-driven product lifecycle management: pipeline advancement, generics and biologics development supported by the ~RMB 2.5bn 2023 investment.
- Brand Finance placed the company among China's top pharma brands in 2024 with a brand value of USD 2.5 billion, an increase of 11% year-on-year.
- Workforce scale (28,000+) and integrated segment model underpin production capacity and market penetration across prescription, OTC and health-product channels.
- Sustainability targets align with national goals (carbon peak by 2030; neutrality by 2060), which are increasingly material to ESG-focused investors and partners.
- For deeper investor insights, ownership dynamics and who's buying the stock, see: Exploring Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Investor Profile: Who's Buying and Why?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Overview
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) operates with a clear, patient-centered mission: 'caring for life and pursuing excellence.' This mission drives its product development, service delivery, and long-term strategy, emphasizing safe, effective medicines and continuous improvement through innovation and quality management.
- Patient-centric focus: prioritizes individual and public health outcomes in R&D, manufacturing, and distribution.
- Quality and safety: adheres to stringent quality control across production lines and supply chains to ensure therapeutic effectiveness and safety.
- Continuous innovation: commits substantial resources to research and development to advance therapies and medical technologies.
The company's mission is reflected in its measurable investments and operational priorities. GBPHC reported R&D expenditure of approximately 2.5 billion RMB in 2023, underscoring the 'pursuing excellence' pillar through new molecule development, clinical trials, and platform technologies. This sustained R&D commitment supports both generic and innovative drug pipelines and bolsters partnerships with academic and industry collaborators.
| Metric (2023, approx.) | Value |
|---|---|
| Revenue | ≈ RMB 31.7 billion |
| Net profit (attributable) | ≈ RMB 2.1 billion |
| Total assets | ≈ RMB 65.4 billion |
| R&D expenditure | ≈ RMB 2.5 billion |
| Employees | ≈ 28,000 |
Key strategic manifestations of the mission and vision include:
- Targeted therapeutic areas: balancing traditional Chinese medicine strengths with modern pharmaceuticals to meet diverse population health needs.
- Manufacturing scale-up: investments in GMP-compliant facilities to maintain supply security and quality standards.
- Market reach: nationwide distribution channels complemented by growing export activities and licensing collaborations.
Operational and governance choices are aligned to safeguard the 'caring for life' principle-risk management systems, pharmacovigilance, and post-market surveillance are prioritized to protect patients. The 'pursuing excellence' aspiration is embedded in performance metrics, R&D KPIs, and cross-functional innovation incentives.
For a deeper dive into the company's background and strategic positioning, see: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited: History, Ownership, Mission, How It Works & Makes Money
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Mission Statement
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) frames its mission around delivering accessible, affordable and compassionate healthcare while pursuing sustainable, inclusive growth. The company's stated vision - "spreading love all over the world" - underpins strategic choices across product development, market expansion, environmental targets and community engagement.- Global health access: expand reach of core pharmaceutical and healthcare products to broader demographics domestically and internationally.
- Affordability and inclusivity: prioritize pricing and distribution strategies that improve access for underserved populations and rural communities.
- Compassion-driven innovation: develop therapies and formulations that respond to public health needs with patient-centered outcomes.
- Sustainability and responsibility: align operations with national carbon targets and corporate social responsibility programs.
- Carbon goals: achieve carbon peak by 2030 and carbon neutrality by 2060, incorporated into factory planning and supply-chain optimization.
- Green manufacturing: invest in low-carbon production lines and build green manufacturing bases emphasizing energy efficiency and waste reduction.
- Community programs: participate in rural revitalization, public-health outreach and charitable healthcare campaigns to raise population-level health outcomes.
- International expansion: broaden export presence and strategic partnerships to extend product availability beyond China's borders.
| Metric / Focus | Detail |
|---|---|
| Stock code | 0874.HK |
| Vision statement | "Spreading love all over the world" |
| Carbon targets | Carbon peak by 2030; carbon neutrality by 2060 |
| Strategic pillars | Affordable healthcare, green manufacturing, community engagement, international expansion |
| Typical initiatives | Green factory construction, rural health projects, pricing policies for essential medicines |
- R&D alignment: prioritize drugs and formulations tackling high-burden diseases and chronic conditions impacting broad demographics.
- Manufacturing modernization: retrofit and construct facilities with energy-saving equipment and emissions controls to meet 2030/2060 goals.
- Distribution and pricing: implement tiered pricing and expanded supplier networks to improve rural and low-income access.
- Partnerships & M&A: pursue collaborations and selective overseas market entry to scale impact while maintaining cost-effectiveness.
- Capital allocation: directing capex toward green production facilities and logistics that lower per-unit carbon intensity.
- KPIs: tracking access metrics (products distributed to rural clinics), environmental KPIs (scope 1/2 emissions trends), and social KPIs (community program reach).
- Reporting: incorporating sustainability disclosures and progress on carbon targets into annual reporting and stakeholder communications.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) - Vision Statement
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) envisions becoming a globally respected leader in healthcare innovation and accessible medicines, delivering sustained value to patients, partners, employees, and shareholders through an integrated approach to research, quality manufacturing, and responsible commercialization. The company's vision aligns with long-term strategic priorities: expanding therapeutic portfolios, deepening presence in both traditional Chinese medicine (TCM) and modern pharmaceuticals, and leveraging digital and scientific advances to improve health outcomes at scale. Core Values- Cooperation - fostering cross-functional teamwork, strategic alliances with research institutions, and supply-chain partnerships to accelerate product development and market reach.
- Relief - prioritizing therapies and OTC products that directly alleviate disease burden and improve patient quality of life across chronic and acute conditions.
- Honesty - committing to regulatory compliance, transparent disclosure, and ethical commercial conduct to maintain stakeholder trust.
- Dedication - maintaining relentless focus on quality, safety, and continuous improvement across R&D, manufacturing, and post-market surveillance.
- Diligence - applying disciplined operational execution, rigorous quality control, and resilient supply-chain management to ensure reliability.
- Innovation - investing in R&D and new technologies to introduce differentiated therapies, formulations, and delivery systems.
| Metric | FY2023 (RMB) | Notes |
|---|---|---|
| Revenue | 31.2 billion | Aggregate sales across prescription drugs, OTC, and healthcare products |
| Net profit (attributable) | 3.05 billion | Post-tax earnings available to shareholders |
| R&D expenditure | 1.03 billion | Investment in discovery, clinical development, and formulation work (~3.3% of revenue) |
| Gross margin | 38.5% | Reflects manufacturing scale, product mix, and pricing |
| Total assets | 58.4 billion | Includes manufacturing sites, inventory, and intangible assets |
| Market capitalization (HKD) | 22.7 billion | HK-listed valuation (ticker: 0874.HK) |
- Cooperation: joint ventures and research collaborations that shorten time-to-market and diversify risk; multiple strategic partnerships across academia and industry.
- Relief: product portfolio skewed toward high-prevalence conditions and widely used OTC remedies to maximize patient access and therapeutic impact.
- Honesty: adherence to regulatory reporting timelines, pharmacovigilance systems, and third-party quality certifications.
- Dedication: continuous CAPEX in manufacturing upgrades and process optimization to support product consistency and scalability.
- Diligence: supply-chain resilience programs and inventory management to reduce stockouts and maintain service levels.
- Innovation: sustained R&D spend with targeted programs in new chemical entities, biologics, and value-added TCM formulations.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.